/Bristol-Myers%20Squibb%20Co_%20logo%20on%20phone%20by-%20Piotr%20Swat%20via%20Shutterstock.jpg)
Bristol-Myers Squibb is poised to announce its second-quarter results this month, and analysts forecast a single-digit decline in the company’s bottom-line figure.
/Johnson%20%26%20Johnson%20location%20sign-by%20JHVEPhoto%20via%20iStock.jpg)
Johnson & Johnson has recently underperformed other pharmaceutical stocks. However, Wall Street analysts are moderately optimistic about the stock’s prospects.
/Lilly(Eli)%20%26%20Co%20logo%20on%20phone-by%20rafapress%20via%20Shutterstock.jpg)
Eli Lilly stock has outperformed the broader market over the past year, and Wall Street analysts remain optimistic about the stock’s prospect.
Viatris has underperformed the broader market over the past year, and analysts remain cautious about the stock's prospects.
As Johnson & Johnson trails the broader market, Wall Street analysts remain cautiously optimistic about the stock's prospects.
Bristol-Myers Squibb stock has significantly trailed the broader market this year, and Wall Street remains wary on the stock’s prospects.
These ETFs can balance stability and long-term growth.